By Sabela Ojea


Seagen said Tuesday its shareholders voted in favor of Pfizer buying the company for $43 billion.

The biotechnology cancer specialist continues to expect to close the deal in late 2023 or early 2024 amid pending regulatory approvals.

In March, Pfizer said it entered into a definitive merger agreement with Seagen for $299 per share in cash to invest in cancer treatments.

The boards of directors of both parties back the transaction.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

05-30-23 1600ET